When we started Vibrynt in 2006, we knew there had to be a better way to treat obesity. For those suffering from morbid obesity, bariatric surgery is now accepted as the best way to achieve weight loss success, however, less than 1% of people will undergo the procedures they need to get better. Clearly, current devices and procedures aren't working for patients' everyday lives. We knew that if we were going to change the results, we would have to change the approach. At Vibrynt, all of our work developing better weight loss devices begins with the belief that you must understand the total experience of obesity to create a total solution for the patient.
Our first product offering is the VIBRYNT PREVAIL® Implant System, which is designed to assist with weight loss by limiting food consumption. The PREVAIL™ System is being evaluated in an FDA-approved clinical research study called the PREVAIL™ U.S. Pivotal Study to support a premarketing application to FDA. It is not available for sale in the United States. The PREVAIL™ System has been approved for sale in Australia, New Zealand and Europe for the treatment of morbid obesity.
Vibrynt is dedicated to creating minimally invasive devices and therapies for patients suffering from obesity by fundamentally improving the patient experience, lowering risk, and improving clinical outcomes and long-term quality of life.